JNJ
Bearish signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Johnson & Johnson
- Nom
- Johnson & Johnson
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $635.9B
- Employés
- 141,700
- PDG
- Joaquin Duato
- Site web
- https://www.jnj.com
- Marché
- ABBVAMGNAZNBMYGILDGSK
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 171 771 titres (~44 812 796,88 $ US)
- Insiders
- Duato Joaquin
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$40,213,934
Avg sell (VWAP, 90d window) $262.94 vs last close $266.30 (+1.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-13
- Liquidity
- Liquid $2,083,743,135/day · 20d vol
- Last synced
-
2026-10-26 21:10:37
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid Timothy | Sell · S | 22,527 | $274.74 | $6,189,068 | Form 4 |
| 2026-08-17 | Taubert Jennifer L | Sell · S | 15,000 | $263.36 | $3,950,400 | Form 4 |
| 2026-08-13 | Duato Joaquin | Sell · S | 102,315 | $261.00 | $26,704,215 | Form 4 |
| 2026-08-06 | Forminard Elizabeth | Sell · S | 6,574 | $255.93 | $1,682,497 | Form 4 |
| 2026-08-05 | Duato Joaquin | Sell · S | 6,523 | $258.74 | $1,687,754 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-09-04 | Ro Khanna | Buy | $15,001 - $50,000 | Filing |
| 2026-09-08 | Lloyd Doggett | Buy | $1,001 - $15,000 | Filing |
| 2026-07-02 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-09-08 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2026-09-04 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-08-27 | Thomas Kean | Sale | $1,001 - $15,000 |
| 2026-08-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-07-30 | Rich McCormick | Sale | $1,001 - $15,000 |
| 2026-07-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-06-29 | Thomas Kean | Sale (Partial) | $1,001 - $15,000 |
| 2026-06-09 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2026-06-02 | Thomas Kean | Sale (Partial) | $1,001 - $15,000 |
| 2026-05-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-03-26 | Thomas Kean | Sale (Partial) | $1,001 - $15,000 |
| 2026-03-19 | Rich McCormick | Sale (Partial) | $1,001 - $15,000 |
| 2026-03-10 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2026-03-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-03-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-23 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-12-09 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2025-11-20 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-05 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-10-10 | Jared Moskowitz | Sale (Partial) | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-19 | Kelly Morrison | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-31 | Thomas Kean | Sale (Partial) | $15,001 - $50,000 |
| 2025-06-24 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-16 | Scott Franklin | Sale (Full) | $15,001 - $50,000 |
| 2025-06-12 | Pete Sessions | Sale (Full) | $15,001 - $50,000 |
| 2025-06-10 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $50,001 - $100,000 |
| 2025-05-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-29 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-01 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-03-31 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-03-24 | George Whitesides | Sale (Full) | $100,001 - $250,000 |
| 2025-03-19 | Sheri Biggs | Sale (Full) | $15,001 - $50,000 |
| 2025-03-07 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-05 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-04 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-01-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-24 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-01-21 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-01-16 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-01-08 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-12-31 | Kevin Hern | Sale (Full) | $100,001 - $250,000 |
| 2024-12-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-12-12 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-12-10 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2024-12-06 | Virginia Ann Foxx | Purchase | $1,001 - $15,000 |
| 2024-11-26 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-11-25 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-11-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-11-08 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-09-26 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-09-10 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-08-07 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-08-07 | Scott Franklin | Purchase | $15,001 - $50,000 |
| 2024-08-02 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-07-16 | Rick Allen | Sale (Full) | $15,001 - $50,000 |
| 2024-07-02 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-07-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-06-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-13 | Rick Allen | Sale (Full) | $15,001 - $50,000 |
| 2024-06-04 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-03-05 | Kevin Hern | Purchase | $1,001 - $15,000 |
| 2024-03-05 | Lloyd Doggett | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2024-02-13 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-03-15 | Rich McCormick | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Bearish signal
Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.03 · operating margin 27%
Suggested stop 257.01, nearest stored support minus 0.5 ATR(3.5% under the last close). Reward/risk to the next stored resistance is 0.34. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 2 Industries Beyond AI With Long-Term Demand Drivers for 2027 As AI dominates Wall Street, healthcare and waste management offer long-term demand drivers for 2027, backed by demographic trends and essential services.
- 2026-10-19 Ds vs. Dividend Stocks: One Protects Your Principal, the Other Could Grow Your Income A CD and a dividend stock can both pay you income in retirement, but they make very different promises, and breaking one of them could cost you far more than a lower yield.
- 2026-10-19 3 Dividend Kings to Buy Now for Protection Against Rising Rates A risk-free bond now pays enough to make most dividend stocks look pointless, but three companies have raised their payouts for over 50 straight years and carry betas low enough to sleep through a rate spike.
- 2026-10-19 Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn''s disease with perianal fistula TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn''s disease SPRING HOUSE, Pa., Oct. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn''s disease (CD).1 The findings build on the previously reported Week 24 results and further support the use of TREMFYA in one of the most difficult-to-treat manifestations of CD 2.
- 2026-10-19 What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs As the midterm election approaches, investors may try to anticipate how different potential outcomes could impact the market. After two years of unified control by the Republican party, polls and analysis are predicting a divided government, with at least one of the chambers of Congress controlled by Democrats beginning in 2027.
- 2026-10-19 Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels.
- 2026-10-19 Johnson & Johnson $JNJ Stock Sold by PineStone Asset Management Inc. PineStone Asset Management Inc. lowered its stake in Johnson and Johnson (NYSE: JNJ) by 5.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,636,744 shares of the company''s stock after selling 97,100 shares during the period. Johnson and Johnson
- 2026-10-19 Johnson & Johnson $JNJ Shares Sold by St. Louis Financial Planners Asset Management LLC St. Louis Financial Planners Asset Management LLC decreased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 16.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,326 shares of the company''s stock after selling 2,195 shares during the
- 2026-10-19 2,302 Shares of Johnson & Johnson $JNJ Bought by USA Financial Formulas USA Financial Formulas acquired a new stake in shares of Johnson and Johnson (NYSE: JNJ) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,302 shares of the company''s stock, valued at approximately $609,000. Several other hedge funds and other institutional investors have
- 2026-10-19 Johnson & Johnson $JNJ Stock Position Lessened by Forum Financial Management LP Forum Financial Management LP lowered its stake in shares of Johnson and Johnson (NYSE: JNJ) by 20.4% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 10,052 shares of the company''s stock after selling 2,573 shares during the period. Forum Financial Management LP''s holdings in
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.9% | 69.1% | 68.8% | 69.3% | 70.3% | |
| Ebit Margin | 35.6% | 19.6% | 18.6% | 24.5% | 24.6% | |
| Ebitda Margin | 43.6% | 27.9% | 27.4% | 33.3% | 34.0% | |
| Operating Profit Margin | 27.2% | 24.9% | 27.5% | 26.3% | 26.6% | |
| Pretax Profit Margin | 34.6% | 18.8% | 17.7% | 24.2% | 24.4% | |
| Continuous Operations Profit Margin | 28.5% | 15.8% | 15.6% | 20.5% | 22.6% | |
| Net Profit Margin | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | |
| Bottom Line Profit Margin | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | |
| Current Ratio | 1.028 | 1.111 | 1.156 | 0.991 | 1.348 | |
| Quick Ratio | 0.765 | 0.863 | 0.914 | 0.807 | 1.119 | |
| Solvency Ratio | 0.292 | 0.197 | 0.432 | 0.225 | 0.262 | |
| Cash Ratio | 0.364 | 0.479 | 0.472 | 0.231 | 0.320 | |
| Price To Earnings Ratio | 18.818 | 24.545 | 11.293 | 25.864 | 21.632 | |
| Price To Earnings Growth Ratio | 0.212 | -0.424 | 0.109 | -1.865 | 0.517 | |
| Forward Price To Earnings Growth Ratio | 0.212 | -0.424 | 0.109 | -1.865 | 0.517 | |
| Price To Earnings Diluted Ratio | 18.818 | 24.756 | 11.424 | 26.248 | 21.964 | |
| Price To Earnings Diluted Growth Ratio | 0.208 | -0.428 | 0.110 | -1.898 | 0.526 | |
| Price To Book Ratio | 6.182 | 4.827 | 5.774 | 6.011 | 6.092 | |
| Price To Sales Ratio | 5.352 | 3.885 | 4.663 | 5.772 | 5.727 | |
| Price To Free Cash Flow Ratio | 25.590 | 17.391 | 21.761 | 26.866 | 22.825 | |
| Price To Operating Cash Flow Ratio | 20.550 | 14.220 | 17.424 | 21.784 | 19.264 | |
| Debt To Assets Ratio | 0.241 | 0.203 | 0.175 | 0.212 | 0.185 | |
| Debt To Equity Ratio | 0.588 | 0.512 | 0.426 | 0.516 | 0.456 | |
| Debt To Capital Ratio | 0.370 | 0.339 | 0.299 | 0.340 | 0.313 | |
| Long Term Debt To Capital Ratio | 0.326 | 0.300 | 0.273 | 0.259 | 0.288 | |
| Financial Leverage Ratio | 2.443 | 2.519 | 2.436 | 2.440 | 2.459 | |
| Working Capital Turnover Ratio | 26.646 | 13.895 | 25.402 | 10.494 | 6.429 | |
| Operating Cash Flow Ratio | 0.453 | 0.482 | 0.492 | 0.380 | 0.518 | |
| Operating Cash Flow Sales Ratio | 0.260 | 0.273 | 0.268 | 0.265 | 0.297 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.803 | 0.818 | 0.801 | 0.811 | 0.844 | |
| Debt Service Coverage Ratio | 3.727 | 3.289 | 5.111 | 1.812 | 6.425 | |
| Interest Coverage Ratio | 26.360 | 29.336 | 30.323 | 76.134 | 114.443 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.888 | 4.056 | 6.604 | 1.661 | 6.216 | |
| Operating Cash Flow Coverage Ratio | 0.512 | 0.662 | 0.777 | 0.535 | 0.694 | |
| Capital Expenditure Coverage Ratio | 5.077 | 5.485 | 5.017 | 5.287 | 6.410 | |
| Dividend Paid And Capex Coverage Ratio | 1.425 | 1.494 | 1.397 | 1.351 | 1.594 | |
| Dividend Payout Ratio | 0.462 | 0.841 | 0.335 | 0.651 | 0.528 | |
| Enterprise Value Multiple | 12.966 | 14.430 | 17.349 | 18.359 | 17.578 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.9% | ▼-1.2% | ▼-1.2% |
| Ebit Margin | 35.6% | ▲16.0% | ▲11.0% |
| Ebitda Margin | 43.6% | ▲15.7% | ▲10.4% |
| Operating Profit Margin | 27.2% | ▲2.2% | ▲0.7% |
| Pretax Profit Margin | 34.6% | ▲15.8% | ▲10.7% |
| Continuous Operations Profit Margin | 28.5% | ▲12.6% | ▲7.8% |
| Net Profit Margin | 28.5% | ▲12.6% | ▲1.6% |
| Bottom Line Profit Margin | 28.5% | ▲12.6% | ▲1.6% |
| Current Ratio | 1.028 | ▼-0.083 | ▼-0.099 |
| Quick Ratio | 0.765 | ▼-0.098 | ▼-0.128 |
| Solvency Ratio | 0.292 | ▲0.095 | ▲0.010 |
| Cash Ratio | 0.364 | ▼-0.115 | ▼-0.009 |
| Price To Earnings Ratio | 18.818 | ▼-5.727 | ▼-1.612 |
| Price To Earnings Growth Ratio | 0.212 | ▲0.635 | ▲0.502 |
| Forward Price To Earnings Growth Ratio | 0.212 | ▲0.635 | ▲0.502 |
| Price To Earnings Diluted Ratio | 18.818 | ▼-5.939 | ▼-1.824 |
| Price To Earnings Diluted Growth Ratio | 0.208 | ▲0.636 | ▲0.504 |
| Price To Book Ratio | 6.182 | ▲1.355 | ▲0.405 |
| Price To Sales Ratio | 5.352 | ▲1.467 | ▲0.272 |
| Price To Free Cash Flow Ratio | 25.590 | ▲8.200 | ▲2.704 |
| Price To Operating Cash Flow Ratio | 20.549 | ▲6.330 | ▲1.901 |
| Debt To Assets Ratio | 0.241 | ▲0.037 | ▲0.037 |
| Debt To Equity Ratio | 0.588 | ▲0.075 | ▲0.088 |
| Debt To Capital Ratio | 0.370 | ▲0.031 | ▲0.038 |
| Long Term Debt To Capital Ratio | 0.326 | ▲0.026 | ▲0.037 |
| Financial Leverage Ratio | 2.443 | ▼-0.076 | ▼-0.017 |
| Working Capital Turnover Ratio | 26.646 | ▲12.751 | ▲10.073 |
| Operating Cash Flow Ratio | 0.453 | ▼-0.029 | ▼-0.012 |
| Operating Cash Flow Sales Ratio | 0.260 | ▼-0.013 | ▼-0.012 |
| Free Cash Flow Operating Cash Flow Ratio | 0.803 | ▼-0.015 | ▼-0.012 |
| Debt Service Coverage Ratio | 3.727 | ▲0.438 | ▼-0.346 |
| Interest Coverage Ratio | 26.360 | ▼-2.976 | ▼-28.959 |
| Short Term Operating Cash Flow Coverage Ratio | 2.888 | ▼-1.168 | ▼-1.397 |
| Operating Cash Flow Coverage Ratio | 0.512 | ▼-0.151 | ▼-0.124 |
| Capital Expenditure Coverage Ratio | 5.077 | ▼-0.408 | ▼-0.379 |
| Dividend Paid And Capex Coverage Ratio | 1.425 | ▼-0.069 | ▼-0.027 |
| Dividend Payout Ratio | 0.462 | ▼-0.379 | ▼-0.102 |
| Enterprise Value Multiple | 12.966 | ▼-1.464 | ▼-3.171 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $504.08B | $345.06B | $397.10B | $461.69B | $450.97B | |
| Enterprise value | $532.30B | $357.59B | $404.57B | $488.44B | $470.24B | |
| EV / Sales | 5.65x | 4.03x | 4.75x | 6.11x | 5.97x | |
| EV / Op. cash flow | 21.70x | 14.74x | 17.75x | 23.05x | 20.09x | |
| EV / Free cash flow | 27.02x | 18.02x | 22.17x | 28.42x | 23.80x | |
| EV / EBITDA | 12.97x | 14.43x | 17.35x | 18.36x | 17.58x | |
| Net debt / EBITDA | 0.69x | 0.51x | 0.32x | 1.01x | 0.72x | |
| Current ratio | 1.03x | 1.11x | 1.16x | 0.99x | 1.35x | |
| Income quality | 0.92x | 1.73x | 1.71x | 1.18x | 1.12x | |
| Graham number | $91 | $62 | $92 | $67 | $71 | |
| Graham net-net | -$32 | -$26 | -$23 | -$27 | -$22 | |
| Tax burden | 82.3% | 84.3% | 233.4% | 92.7% | 108.9% | |
| Interest burden | 97.1% | 95.7% | 95.1% | 98.6% | 99.1% | |
| Working capital | $1.50B | $5.57B | $7.21B | -$508.0M | $15.75B | |
| Invested capital | $123.84B | $107.91B | $97.84B | $92.01B | $116.35B | |
| Return on assets | 13.5% | 7.8% | 21.0% | 9.6% | 11.5% | |
| Operating ROA | 13.5% | 12.7% | 13.2% | 11.4% | 11.7% | |
| Return on tangible assets | 26.8% | 14.3% | 36.3% | 15.9% | 20.8% | |
| Return on equity | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% | |
| Return on invested capital | 13.7% | 13.8% | 16.6% | 12.3% | 13.8% | |
| Return on capital employed | 17.6% | 17.1% | 19.3% | 16.0% | 15.3% | |
| Earnings yield | 5.3% | 4.1% | 8.9% | 3.9% | 4.6% | |
| Free cash flow yield | 3.9% | 5.8% | 4.6% | 3.7% | 4.4% | |
| Capex / Op. cash flow | 19.7% | 18.2% | 19.9% | 18.9% | 15.6% | |
| Capex / Depreciation | 64.4% | 60.3% | 60.7% | 57.5% | 49.4% | |
| Capex / Sales | 5.1% | 5.0% | 5.3% | 5.0% | 4.6% | |
| SG&A / Sales | 25.1% | 24.7% | 23.6% | 25.3% | 25.5% | |
| R&D / Sales | 15.6% | 19.4% | 17.7% | 17.7% | 18.1% | |
| Stock comp / Sales | 1.4% | 1.3% | 1.4% | 1.4% | 1.4% | |
| Intangibles / Total assets | 49.8% | 45.4% | 42.2% | 39.8% | 44.9% | |
| Days sales outstanding | 67d | 78d | 64d | 77d | 88d | |
| Days payables outstanding | 145d | 137d | 132d | 147d | 172d | |
| Operating cycle | 238d | 243d | 217d | 230d | 250d | |
| Cash conversion cycle | 93d | 106d | 85d | 83d | 78d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+46.1%EV / Sales ▲+40.4%EV / EBITDA ▼-10.1%EV / Op. cash flow ▲+6.964Earnings yield ▲+0.012Graham number ▲+28.829
Profitability
Return on equity ▲+0.132Return on assets ▲+0.056Return on invested capital -0.000Return on capital employed ▲+0.006Operating ROA ▲+0.008Income quality ▼-0.810Tax burden ▼-0.020
Efficiency
Days sales outstanding ▼-11.213Days payables outstanding ▲+7.657Operating cycle ▼-5.357Cash conversion cycle ▼-13.014Capex / Sales ▲+0.001R&D / Sales ▼-0.038
Balance-sheet strength
Current ratio ▼-0.083Net debt / EBITDA ▲+0.182Working capital ▼-4074000000.000Invested capital ▲+15934000000.000Intangibles / Total assets ▲+0.044
Change over 5 years
Valuation
Market cap ▲+11.8%EV / Sales ▼-5.4%EV / EBITDA ▼-26.2%EV / Op. cash flow ▲+1.613Earnings yield ▲+0.007Graham number ▲+20.382
Profitability
Return on equity ▲+0.047Return on assets ▲+0.020Return on invested capital ▼-0.001Return on capital employed ▲+0.023Operating ROA ▲+0.018Income quality ▼-0.206Tax burden ▼-0.266
Efficiency
Days sales outstanding ▼-21.435Days payables outstanding ▼-27.768Operating cycle ▼-12.245Cash conversion cycle ▲+15.524Capex / Sales ▲+0.005R&D / Sales ▼-0.026
Balance-sheet strength
Current ratio ▼-0.321Net debt / EBITDA ▼-0.033Working capital ▼-14255000000.000Invested capital ▲+7489000000.000Intangibles / Total assets ▲+0.049